DelveInsight’s latest report, “Corneal Edema: Market Insights, Epidemiology, and Market Forecast-2034” combines robust epidemiological data with corneal edema market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the market for corneal edema in the US is expected to grow positively from ~USD 489 million in 2022 over the coming years. This growth is attributed to improved diagnostic capabilities, a rising aging population contributing to an increase in corneal edema patient population, and the emergence of new and effective corneal edema treatments during the forecast period.
The report also provides an in-depth epidemiological analysis and forecasts until 2034, segmented by total diagnosed prevalent cases of corneal edema, etiology-specific corneal edema diagnosed prevalent cases, and total treatable corneal edema cases in the US.
According to research conducted by DelveInsight’s analysts, the total diagnosed prevalence of corneal edema is approximately 1.18 million in 2023. The corneal edema diagnosed prevalent cases are further categorized based on mechanical, dystrophic, and inflammatory causes.
Discover evolving trends in Corneal Edema patient pool forecasts—Download sample report on Corneal Edema Epidemiology 2034 Analysis now!
The current treatment approach for corneal edema is dynamic and involves a tailored strategy based on the underlying cause and severity of the condition. Initial management often includes hypertonic saline solutions or hyperosmotic agents to reduce inflammation and draw excess fluid from the cornea. In cases where the corneal endothelium is severely compromised, surgical interventions or laser procedures, such as Selective Laser Trabeculoplasty (SLT), may be considered, particularly in cases associated with secondary glaucoma.
The treatment gap in corneal edema lies primarily in the absence of a universally effective and minimally invasive therapy that addresses the underlying causes and reverses the condition instead of focusing on managing symptoms or replacing damaged corneal tissue.
DelveInsight’s analysis reveals that a decent number of companies are launching clinical trials to address this unmet need in the corneal edema treatment landscape. The clinical development pipeline includes drugs such as EO2002 (Emmetrope Ophthalmics LLC), TTHX1114 (Trefoil Therapeutics), GLANATEC (D. Western Therapeutics Institute (DWTI)/Kowa Ltd.), AURN001 (Aurion Biotech) and STN1010904 (Santen Pharmaceutical), among others which are expected to enter the market during the forecast period and going to impact the trajectory of corneal edema market.
Unlock which corneal edema emerging drug is expected to capture the largest market share in 7MM by 2034 market, visit Corneal Edema Market Insights
In December 2024, AURN001, an allogeneic cell therapy by Aurion Biotech showed positive results in Phase 1/2 trials for the US market. EO2002, a nonsurgical cell therapy by Emmetrope Ophthalmics LLC demonstrated improvement in best-corrected visual acuity (BCVA) during a Phase 1 extension study as of November 2024. These developments highlight the momentum in this field.
Although corneal edema presents significant challenges, particularly due to the difficulty of early-stage detection, which can lead to ineffective management and increased severity, the emergence of more precise and sensitive diagnostic methods, along with novel therapies, is expected to expand treatment options and drive market growth.
Download the report to understand which factors are driving Corneal Edema market trends @ Corneal Edema Market Trends.
Table of Contents
|
1. |
Key Insights |
|
2. |
Report Introduction |
|
3. |
Corneal Edema Market Overview at a Glance |
|
3.1. |
Market Share (%) Distribution by Therapies of Corneal Edema in 2020 |
|
3.2. |
Market Share (%) Distribution by Therapies of Corneal Edema in 2034 |
|
4. |
Epidemiology and Market Methodology of Corneal Edema |
|
5. |
Executive Summary of Corneal Edema |
|
6. |
Key Events |
|
7. |
Corneal Edema: Disease Background and Overview |
|
7.1. |
Introduction |
|
7.2. |
Etiology |
|
7.3. |
Pathophysiology |
|
7.4. |
Diagnosis |
|
7.4.1. |
Differential Diagnosis |
|
7.4.2. |
Diagnostic Algorithm |
|
7.4.3. |
Diagnostic Guidelines |
|
7.4.3.1. |
American Academy of Ophthalmology (AAO) 2018 Guideline for Corneal Edema and Opacification Preferred Practice Pattern |
|
7.5. |
Management |
|
7.5.1. |
Treatment Algorithm |
|
7.5.2. |
Treatment Guidelines |
|
7.5.2.1. |
AAO 2018 Guideline for Corneal Edema and Opacification Preferred Practice Pattern |
|
8. |
Corneal Edema Epidemiology and Patient Population |
|
8.1. |
Key Findings |
|
8.2. |
Assumptions and Rationale |
|
8.2.1. |
Etiology-specific Diagnosed Prevalent Cases of Corneal Edema |
|
8.3. |
The United States |
|
8.3.1. |
Total Diagnosed Prevalent Cases of Corneal Edema in the US |
|
8.3.2. |
Etiology-specific Diagnosed Prevalent Cases of Corneal Edema in the US |
|
9. |
Corneal Edema Patient Journey |
|
10. |
Corneal Edema Emerging Drugs |
|
10.1. |
Key Cross Competition |
|
10.2. |
EO2002: Emmetrope Ophthalmics LLC (“Emmecell”) |
|
10.2.1. |
Product Description |
|
10.2.2. |
Other Development Activities |
|
10.2.3. |
Clinical Development |
|
10.2.4. |
Clinical Trial Information |
|
10.2.5. |
Safety and Efficacy |
|
10.2.6. |
Product Profile |
|
10.2.7. |
Analysts’ Views |
|
10.3. |
TTHX1114: Trefoil Therapeutics |
|
10.3.1. |
Product Description |
|
10.3.2. |
Other Developmental Activities |
|
10.3.3. |
Clinical Development |
|
10.3.4. |
Clinical Trials Information |
|
10.3.5. |
Safety and Efficacy |
|
10.3.6. |
Product Profile |
|
10.3.7. |
Analyst Views |
|
10.4. |
GLANATEC (ripasudil/K-321): D. Western Therapeutics Institute (DWTI)/Kowa Ltd. |
|
10.4.1. |
Product Description |
|
10.4.2. |
Other Development Activities |
|
10.4.3. |
Clinical Development |
|
10.4.4. |
Clinical Trial Information |
|
10.4.5. |
Product Profile |
|
10.4.6. |
Analysts’ Views |
|
10.5. |
STN1010904 (sirolimus)/AE001: Santen Pharmaceutical/ Actual Eyes |
|
10.5.1. |
Product Description |
|
10.5.2. |
Other Developmental Activities |
|
10.5.3. |
Clinical Development |
|
10.5.4. |
Clinical Trials Information |
|
10.5.5. |
Product Profile |
|
10.5.6. |
Analyst Views |
|
11. |
Corneal Edema: Market Analysis |
|
11.1. |
Key Findings |
|
11.2. |
Corneal Edema Market Outlook |
|
11.3. |
Conjoint Analysis |
|
11.4. |
Key Market Forecast Assumptions |
|
11.5. |
Total Market Size of Corneal Edema in the US |
|
11.6. |
Market Size of Corneal Edema by Therapies in the US |
|
12. |
Key Opinion Leaders’ Views |
|
13. |
SWOT Analysis |
|
14. |
Corneal Edema Unmet Needs |
|
15. |
Market Access and Reimbursement |
|
15.1. |
The United States |
|
15.1.1. |
Center for Medicare and Medicaid Services (CMS) |
|
16. |
Appendix |
|
16.1. |
Bibliography |
|
16.2. |
Acronyms and Abbreviations |
|
16.3. |
Report Methodology |
|
17. |
DelveInsight Capabilities |
|
18. |
Disclaimer |
Related Reports
Fuchs Endothelial Corneal Dystrophy Pipeline Insight
Fuchs Endothelial Corneal Dystrophy Pipeline Insight provides comprehensive insights about the Fuchs Endothelial Corneal pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Fuchs Endothelial Corneal companies, including Trefoil Therapeutics, Kowa Pharmaceutical and Santen Pharmaceutical
Media Contact
Company Name: DelveInsight
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/